Literature DB >> 20128552

Clinical and histologic ocular findings in pompe disease.

Tammy L Yanovitch1, Suhrad G Banugaria, Alan D Proia, Priya S Kishnani.   

Abstract

PURPOSE: Limited information is available on the ocular findings in patients with Pompe disease.
METHOD: This study summarizes this information with a systematic literature review; reports the ocular histologic findings seen in a deceased infant with Pompe disease who was receiving enzyme replacement therapy and in a deceased adult with late-onset Pompe disease; and notes the new observation of ptosis in children with infantile-onset Pompe disease who are receiving enzyme replacement therapy.
RESULTS: Six articles were found on the ultrastructural-histopathologic eye findings in Pompe disease. Previously reported clinical ocular findings included strabismus and ptosis. Glycogen accumulation and vacuolar myopathy have been seen histologically.
CONCLUSION: Based on these clinical and histologic reports, patients with Pompe disease may have an increased incidence of ocular abnormalities, such as ptosis and strabismus, and therefore should undergo ophthalmologic examination. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128552     DOI: 10.3928/01913913-20100106-08

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  17 in total

1.  Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease.

Authors:  Sang-Oh Han; Songtao Li; Jeffrey I Everitt; Dwight D Koeberl
Journal:  Hum Gene Ther       Date:  2019-04-05       Impact factor: 5.695

2.  Cardiac Pathology in Glycogen Storage Disease Type III.

Authors:  S L Austin; A D Proia; M J Spencer-Manzon; J Butany; S B Wechsler; P S Kishnani
Journal:  JIMD Rep       Date:  2012-01-31

3.  Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease.

Authors:  Loren D M Pena; Alan D Proia; Priya S Kishnani
Journal:  JIMD Rep       Date:  2015-03-13

4.  Salmeterol enhances the cardiac response to gene therapy in Pompe disease.

Authors:  Sang-Oh Han; Songtao Li; Dwight D Koeberl
Journal:  Mol Genet Metab       Date:  2016-03-18       Impact factor: 4.797

5.  Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.

Authors:  Ankit K Desai; Crista K Walters; Heidi L Cope; Zoheb B Kazi; Stephanie M DeArmey; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-12-23       Impact factor: 4.797

6.  Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.

Authors:  Fabian P S Yu; Benjamin S Sajdak; Jakub Sikora; Alexander E Salmon; Murtaza S Nagree; Jiří Gurka; Iris S Kassem; Daniel M Lipinski; Joseph Carroll; Jeffrey A Medin
Journal:  Am J Pathol       Date:  2018-11-23       Impact factor: 4.307

7.  Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.

Authors:  Songtao Li; Baodong Sun; Mats I Nilsson; Andrew Bird; Mark A Tarnopolsky; Beth L Thurberg; Deeksha Bali; Dwight D Koeberl
Journal:  FASEB J       Date:  2012-09-19       Impact factor: 5.191

8.  β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.

Authors:  Dwight D Koeberl; Songtao Li; Jian Dai; Beth L Thurberg; Deeksha Bali; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-11-11       Impact factor: 4.797

9.  Ocular and histologic findings in a series of children with infantile pompe disease treated with enzyme replacement therapy.

Authors:  S Grace Prakalapakorn; Alan D Proia; Tammy L Yanovitch; Stephanie DeArmey; Nancy J Mendelsohn; Kyrieckos A Aleck; Priya S Kishnani
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2014-08-20       Impact factor: 1.402

10.  A study of glycogen storage disease with 99Tcm-MIBI gated myocardial perfusion imaging.

Authors:  L G Wei; J Q Gao; X M Liu; J M Huang; X Z Li
Journal:  Ir J Med Sci       Date:  2013-04-25       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.